3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
3
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Lymphoma, Mantle-Cell
5
Lymphoma, Non-Hodgkin
4
Multiple Myeloma
3
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, B-Cell
2
Waldenstrom Macroglobulinemia
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Prolymphocytic
1
Leukemia, Hairy Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Burkitt Lymphoma
1
Advanced Haematological Malignancies
1
Interventions
Rituximab
52
Cyclophosphamide
42
fludarabine phosphate
41
Peripheral Blood Stem Cell Transplantation
41
Whole-Body Irradiation
26
Mycophenolic Acid
25
Cyclosporine
21
Bortezomib
21
Dexamethasone
19
Busulfan
18
Tacrolimus
17
Etoposide
17
Filgrastim
15
Antilymphocyte Serum
14
Methotrexate
13
Melphalan
13
ibrutinib
12
Radiotherapy
11
Calcium Dobesilate
9
Sirolimus
8
Lenalidomide
8
Cyclosporins
8
Methylprednisolone
7
Flow Cytometry
7
Everolimus
7
Carboplatin
7
ibritumomab tiuxetan
6
zanubrutinib
5
fludarabine
5
Transplantation
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Waldenstrom Macroglobulinemia
×
acalabrutinib
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts